Stemline Therapeutics Inc (NASDAQ:STML) CEO Ivan Bergstein Sells 56,316 Shares

Stemline Therapeutics Inc (NASDAQ:STML) CEO Ivan Bergstein sold 56,316 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $15.08, for a total value of $849,245.28. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ivan Bergstein also recently made the following trade(s):

  • On Monday, June 24th, Ivan Bergstein sold 10,822 shares of Stemline Therapeutics stock. The stock was sold at an average price of $15.49, for a total value of $167,632.78.

STML traded down $0.35 during trading on Friday, hitting $13.47. The stock had a trading volume of 269,856 shares, compared to its average volume of 452,953. The stock has a 50 day simple moving average of $14.27. The company has a market capitalization of $588.44 million, a price-to-earnings ratio of -4.51 and a beta of 1.33. Stemline Therapeutics Inc has a one year low of $7.82 and a one year high of $17.85. The company has a current ratio of 5.07, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01.

Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The company had revenue of $5.05 million during the quarter, compared to analyst estimates of $2.61 million. As a group, sell-side analysts expect that Stemline Therapeutics Inc will post -2.14 EPS for the current fiscal year.

A number of research firms recently weighed in on STML. HC Wainwright set a $35.00 target price on Stemline Therapeutics and gave the stock a “buy” rating in a report on Thursday, June 20th. Wedbush reissued a “buy” rating and set a $95.00 target price on shares of Global Blood Therapeutics in a report on Monday, May 13th. BidaskClub raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 4th. ValuEngine raised Vermillion from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Finally, Roth Capital reissued a “buy” rating on shares of Resverlogix in a report on Thursday, May 23rd. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $25.20.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its holdings in shares of Stemline Therapeutics by 47.2% during the 4th quarter. Rhumbline Advisers now owns 37,138 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 11,911 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Stemline Therapeutics during the 4th quarter worth approximately $108,000. BlackRock Inc. increased its holdings in shares of Stemline Therapeutics by 4.9% during the 4th quarter. BlackRock Inc. now owns 2,065,239 shares of the biopharmaceutical company’s stock worth $19,618,000 after acquiring an additional 95,747 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Stemline Therapeutics by 26.5% during the 4th quarter. Bank of New York Mellon Corp now owns 134,756 shares of the biopharmaceutical company’s stock worth $1,281,000 after acquiring an additional 28,198 shares during the last quarter. Finally, Citigroup Inc. increased its holdings in shares of Stemline Therapeutics by 116.2% during the 4th quarter. Citigroup Inc. now owns 77,957 shares of the biopharmaceutical company’s stock worth $741,000 after acquiring an additional 41,897 shares during the last quarter. Institutional investors and hedge funds own 77.66% of the company’s stock.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Story: How to calculate the annual rate of depreciation

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.